These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 7512157

  • 1. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    Earl PL, Broder CC, Long D, Lee SA, Peterson J, Chakrabarti S, Doms RW, Moss B.
    J Virol; 1994 May; 68(5):3015-26. PubMed ID: 7512157
    [Abstract] [Full Text] [Related]

  • 2. Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.
    Richardson TM, Stryjewski BL, Broder CC, Hoxie JA, Mascola JR, Earl PL, Doms RW.
    J Virol; 1996 Feb; 70(2):753-62. PubMed ID: 8551612
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
    Moore JP, Sattentau QJ, Wyatt R, Sodroski J.
    J Virol; 1994 Jan; 68(1):469-84. PubMed ID: 7504741
    [Abstract] [Full Text] [Related]

  • 5. Antibody-dependent cellular cytotoxicity directed against cells expressing human immunodeficiency virus type 1 envelope of primary or laboratory-adapted strains by human and chimpanzee monoclonal antibodies of different epitope specificities.
    Alsmadi O, Tilley SA.
    J Virol; 1998 Jan; 72(1):286-93. PubMed ID: 9420226
    [Abstract] [Full Text] [Related]

  • 6. Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.
    Edinger AL, Ahuja M, Sung T, Baxter KC, Haggarty B, Doms RW, Hoxie JA.
    J Virol; 2000 Sep; 74(17):7922-35. PubMed ID: 10933700
    [Abstract] [Full Text] [Related]

  • 7. Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein.
    Wyatt R, Desjardin E, Olshevsky U, Nixon C, Binley J, Olshevsky V, Sodroski J.
    J Virol; 1997 Dec; 71(12):9722-31. PubMed ID: 9371638
    [Abstract] [Full Text] [Related]

  • 8. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P, Earl PL, Sironi F, Santoro F, Ripamonti C, Scarlatti G, Longhi R, Berger EA, Burastero SE.
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [Abstract] [Full Text] [Related]

  • 9. Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein.
    Earl PL, Broder CC, Doms RW, Moss B.
    J Virol; 1997 Apr; 71(4):2674-84. PubMed ID: 9060620
    [Abstract] [Full Text] [Related]

  • 10. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
    Stamatatos L, Lim M, Cheng-Mayer C.
    AIDS Res Hum Retroviruses; 2000 Jul 01; 16(10):981-94. PubMed ID: 10890360
    [Abstract] [Full Text] [Related]

  • 11. Effects of oligomerization on the epitopes of the human immunodeficiency virus type 1 envelope glycoproteins.
    Gorny MK, VanCott TC, Williams C, Revesz K, Zolla-Pazner S.
    Virology; 2000 Feb 15; 267(2):220-8. PubMed ID: 10662617
    [Abstract] [Full Text] [Related]

  • 12. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, Nádas A, Zolla-Pazner S.
    J Virol; 2000 Aug 15; 74(15):7096-107. PubMed ID: 10888650
    [Abstract] [Full Text] [Related]

  • 13. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
    Park EJ, Vujcic LK, Anand R, Theodore TS, Quinnan GV.
    J Virol; 1998 Sep 15; 72(9):7099-107. PubMed ID: 9696803
    [Abstract] [Full Text] [Related]

  • 14. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY, Hariharan K, Nara PL, Sodroski J, Moore JP.
    J Virol; 1994 Sep 15; 68(9):5854-62. PubMed ID: 7520095
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of conformation-dependent anti-gp120 murine monoclonal antibodies produced by immunization with monomeric and oligomeric human immunodeficiency virus type 1 envelope proteins.
    Sugiura W, Broder CC, Moss B, Earl PL.
    Virology; 1999 Feb 15; 254(2):257-67. PubMed ID: 9986792
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Identification of human immunodeficiency virus type 1 glycoprotein gp120/gp41 interacting sites by the idiotypic mimicry of two monoclonal antibodies.
    Lopalco L, Longhi R, Ciccomascolo F, De Rossi A, Pelagi M, Andronico F, Moore JP, Schulz T, Beretta A, Siccardi AG.
    AIDS Res Hum Retroviruses; 1993 Jan 15; 9(1):33-9. PubMed ID: 7678970
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.